Can CAR-T cancer treatments be fine-tuned to avoid toxic side effects? Monday, December 5, 2016
At the ASH meeting in San Diego, Kite Pharma and Novartis presented impressive data on their chimeric antigen receptor T-cell (CAR-T) therapies to treat blood cancers, and both appear to be on track to file for FDA approval soon. But concerns about toxic side effects continue to dog this emerging form of immunotherapy. Now a set of researchers at the Fred Hutchinson Cancer Research Center in… Read More
Rivals Kite and Novartis post new CAR-T data as both plot FDA approval Monday, December 5, 2016
Despite looking to have taken a big step back from cell therapy work this year, Novartis hopes to be first to market a new CAR-T med as it plans to file early next year with the FDA, but rival Kite Pharma is hot on its heels as it starts a rolling submission with the regulator.
10. Work backward from your target company profile and your target product profile. Is your vision to create a single-product company or one with a rich pipeline of drugs? Do you want to hold on for the long run or sell early? Your answer to what kind of company you want to build has dozens of strategic implications. When you finally have a product in the clinic, ask what target product profile will actually compel a clinician to prescribe?… Read More
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.